TL;DR
This study reveals a surprising, non-splicing role for the splicing factor SF3B1 in promoting cancer. SF3B1 directly interacts with the HIF1α/HIF1β complex, enhancing its ability to bind to DNA and activate genes crucial for cancer survival and progression, particularly under low-oxygen conditions. This discovery offers a new therapeutic target for aggressive cancers.
What Problem Does This Paper Address?
Mutations in the splicing factor SF3B1 are common in various cancers and are known to drive tumor progression by altering gene splicing. While studies have also shown a correlation between wildtype SF3B1 expression levels and tumor malignancy, the underlying mechanisms for this correlation have remained unclear. This paper investigates how elevated levels of functional SF3B1, not just mutated forms, contribute to cancer aggressiveness, specifically exploring its role in the context of hypoxia, a common feature of solid tumors.
Methods
The researchers employed a multi-pronged approach:
- Molecular Biology Techniques: Western blotting, immunoprecipitation (IP), and co-immunoprecipitation (CoIP) were used to confirm protein interactions and levels.
- Cell-based Assays: Luciferase reporter assays were used to measure the transcriptional activity of HIF1α targets. Proliferation assays assessed cancer cell growth under different conditions.
- Genomic and Transcriptomic Analysis: RNA sequencing (RNA-seq) was used to analyze gene expression changes. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) was employed to map where HIF1α binds to DNA.
- In Vivo Models: Genetically engineered mouse models (KPC mice) were used to study the role of SF3B1 in pancreatic cancer development. Organoid cultures from these mice were also utilized.
- Bioinformatics: Analysis of TCGA datasets was performed to correlate SF3B1 expression with patient survival and genetic alterations.
Datasets
- TCGA Pan-Cancer Atlas: Used for analyzing SF3B1 expression, hypoxia signatures, and survival data across various cancer types.
- Human Cancer Cell Lines: Various cell lines (e.g., PANC-1, SK-MEL-28, MDA-MB-231, Mia-PaCa-2, HEK293T, AsPC-1, BxPC-3) were used for in vitro experiments.
- Patient-Derived Organoids: Established from pancreatic ductal adenocarcinoma (PDAC) patients.
- Genetically Engineered Mouse Models: KPC (KrasG12D/+; Trp53R172H/+; Ptf1a-Cre) mice and their Sf3b1 heterozygous knockout counterparts (KPCS) were used.
- ChRCC Patient Samples: Used for analyzing SF3B1 expression and chromosome 2 status.
Key Insights and Ideas
- SF3B1 is a Splicing-Independent Activator of HIF Signaling: This is the central finding. SF3B1 doesn't just affect splicing; it directly enhances the activity of the HIF1α/HIF1β complex.
- SF3B1 Forms a Heterotrimer with HIF1α and HIF1β: The study demonstrates that SF3B1 acts as a molecular bridge, facilitating the formation of a functional HIF1 complex.
- Enhanced DNA Binding: The SF3B1-containing HIF1 complex binds more efficiently to hypoxia-response elements (HREs) on DNA, leading to increased transcription of HIF target genes.
- Cancer-Specific Roles: The importance of SF3B1 in HIF signaling is context-dependent. It's crucial for hypoxic pancreatic cancer progression but less critical in normoxic chromophobe renal cell carcinoma (chRCC).
- Therapeutic Potential: Inhibiting the SF3B1-HIF1α interaction could be a targeted strategy to combat cancers that rely on HIF signaling for survival and growth.
Key Results
- Correlation with Malignancy: High SF3B1 expression correlated with increased malignancy and poorer survival in several cancer types (PDAC, PCA, HCC, BRCA).
- SF3B1 Upregulates HIF Target Genes: Overexpression of SF3B1 led to increased expression of HIF target genes like VEGFA, BNIP3, and CA9. Conversely, SF3B1 knockdown reduced their expression.
- Direct Interaction: SF3B1 was shown to physically interact with HIF1α and HIF1β, forming a heterotrimer. This interaction was mapped to the bHLH-PAS-A-PAS-B domain of HIF1α.
- Impaired HIF Binding Without SF3B1: Knockdown of SF3B1 significantly reduced HIF1α binding to HREs, impairing the transcriptional response to hypoxia.
- Reduced PDAC Growth: Heterozygous deletion of Sf3b1 in a mouse model of pancreatic cancer (KPCS mice) significantly hampered tumor formation and progression, correlating with impaired HIF signaling.
- Tolerance in chRCC: Loss of SF3B1 heterozygosity was well-tolerated in chromophobe renal cell carcinoma (chRCC), a cancer type that does not heavily rely on HIF-driven glycolysis.
Limitations and Future Work
- Splicing vs. Non-Splicing Role: While the study strongly suggests a splicing-independent role, further work might be needed to definitively rule out any subtle effects on splicing that could contribute to the observed phenotypes.
- Oncogenic Mutations: The study found that an oncogenic SF3B1 mutation (K700E) did not enhance HIF binding, suggesting that the pro-tumorigenic effects of mutated SF3B1 might operate through different mechanisms than wildtype SF3B1's role in HIF activation.
- Therapeutic Development: The authors propose that inhibiting the SF3B1-HIF1α interaction could be a novel therapeutic strategy. Future work would involve developing specific inhibitors for this interaction and testing their efficacy in preclinical models.
- Broader Cancer Relevance: While the study focused on PDAC and chRCC, further investigation into the role of SF3B1 in HIF activation across a wider range of cancers would be valuable.
Summary updated